MAPK1 and colorectal carcinoma: Study showed that GpS (500, 750 mg/kg) was able to dose-dependently upregulated the expression of Prdx1 and Prdx2, and downregulate the expression of Raf-1, which acted as an anticancer agent by inhibiting the RAS/RAF/MEK/ERK signaling pathway in ApcMin/+ CRC mice (Tai et al., 2016).